( May 12, 2026, 07:01 GMT | Official Statement) -- MLex Summary: Novartis' proposal to acquire 100 percent of the issued and outstanding capital stock of US‑based biotech Excellergy will be reviewed by Australia's competition watchdog. In a statement Tuesday, the Australian Competition & Consumer Commission said Novartis, headquartered in Switzerland, supplies a range of medicines to customers in Australia, including treatments for chronic spontaneous urticaria. Excellergy is developing early‑stage anti‑IgE allergy therapies, including a Phase 1 antibody, with no commercial products or revenue and only limited ties to Australia for clinical trials. Submissions are due by May 19.Statement follows. Questionnaire attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.